Profile data is unavailable for this security.
About the company
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
- Revenue in USD (TTM)6.48m
- Net income in USD-190.05m
- Incorporated2007
- Employees181.00
- LocationFate Therapeutics Inc12278 Scripps Summit DriveSAN DIEGO 92131United StatesUSA
- Phone+1 (858) 875-1803
- Fax+1 (302) 636-5454
- Websitehttps://fatetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ADC Therapeutics SA | 68.62m | -227.23m | 334.74m | 273.00 | -- | -- | -- | 4.88 | -2.77 | -2.77 | 0.8368 | -2.35 | 0.1769 | 0.2683 | 2.91 | 251,351.60 | -56.99 | -48.41 | -69.99 | -55.63 | 93.30 | -- | -322.09 | -308.62 | 4.35 | -4.14 | 1.85 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
Absci Corp | 5.35m | -109.19m | 335.86m | 155.00 | -- | 1.40 | -- | 62.81 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
Kyverna Therapeutics Inc | 0.00 | -75.92m | 347.08m | 100.00 | -- | 0.9615 | -- | -- | -1.73 | -1.73 | 0.00 | 8.37 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0045 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
Anavex Life Sciences Corp | 0.00 | -40.59m | 349.57m | 40.00 | -- | 2.56 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
Organogenesis Holdings Inc | 435.47m | 5.82m | 352.64m | 862.00 | 61.18 | 1.26 | 16.61 | 0.8098 | 0.0435 | 0.0435 | 3.28 | 2.11 | 0.9628 | 4.08 | 4.63 | 505,190.30 | 1.29 | 5.46 | 1.56 | 6.90 | 75.07 | 74.94 | 1.34 | 4.81 | 2.41 | 8.78 | 0.1955 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
Aura Biosciences Inc | 0.00 | -78.65m | 354.23m | 88.00 | -- | 1.70 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
Cabaletta Bio Inc | 0.00 | -76.87m | 356.76m | 118.00 | -- | 1.61 | -- | -- | -1.73 | -1.73 | 0.00 | 4.60 | 0.00 | -- | -- | 0.00 | -44.70 | -33.76 | -48.55 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
Fate Therapeutics Inc | 6.48m | -190.05m | 366.54m | 181.00 | -- | 0.8599 | -- | 56.58 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Nkarta Inc | 0.00 | -116.20m | 370.66m | 150.00 | -- | 0.7824 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Editas Medicine Inc | 69.41m | -166.13m | 373.36m | 265.00 | -- | 1.27 | -- | 5.38 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
IGM Biosciences Inc | 2.11m | -236.92m | 377.75m | 216.00 | -- | 2.34 | -- | 179.45 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Fulcrum Therapeutics Inc | 2.51m | -99.43m | 379.14m | 76.00 | -- | 1.77 | -- | 151.05 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
AC Immune SA | 16.38m | -60.40m | 383.90m | 133.00 | -- | 2.40 | -- | 23.44 | -0.6773 | -0.6773 | 0.1843 | 1.61 | 0.088 | -- | 61.04 | 123,144.50 | -32.45 | -18.25 | -35.04 | -19.52 | -- | -- | -368.77 | -148.29 | -- | -- | 0.0225 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
Lyell Immunopharma Inc | 68.00k | -228.34m | 384.96m | 224.00 | -- | 0.6382 | -- | 5,661.15 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -115.28m | 397.05m | 33.00 | -- | 1.63 | -- | -- | -4.70 | -4.70 | 0.00 | 5.50 | 0.00 | -- | -- | 0.00 | -76.12 | -- | -82.46 | -- | -- | -- | -- | -- | -- | -2.15 | 0.0856 | -- | -- | -- | -260.87 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 07 Jun 2024 | 13.18m | 11.58% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 9.84m | 8.65% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 8.04m | 7.06% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 6.88m | 6.04% |
Deep Track Capital LPas of 31 Mar 2024 | 5.57m | 4.90% |
Bellevue Asset Management AGas of 31 Mar 2024 | 4.84m | 4.25% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.13m | 2.75% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.82m | 2.48% |
D. E. Shaw & Co. LPas of 31 Mar 2024 | 2.73m | 2.40% |
Suvretta Capital Management LLCas of 31 Mar 2024 | 2.56m | 2.25% |